Wordt geladen...

ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer

Although EZH2 enzymatic inhibitors have shown anti-tumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here we identify ZRANB1 as the EZH2 deubiquitinase. ZRANB1...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cell Rep
Hoofdauteurs: Zhang, Peijing, Xiao, Zhenna, Wang, Shouyu, Zhang, Mutian, Wei, Yongkun, Hang, Qinglei, Kim, Jongchan, Yao, Fan, Rodriguez-Aguayo, Cristian, Ton, Baochau N., Lee, Minjung, Wang, Yumeng, Zhou, Zhicheng, Zeng, Liyong, Hu, Xiaoyu, Lawhon, Sarah E., Siverly, Ashley N., Su, Xiaohua, Li, Jia, Xie, Xiaoping, Cheng, Xuhong, Liu, Liang-Chiu, Chang, Hui-Wen, Chiang, Shu-Fen, Lopez-Berestein, Gabriel, Sood, Anil K., Chen, Junjie, You, M. James, Sun, Shao-Cong, Liang, Han, Huang, Yun, Yang, Xianbin, Sun, Deqiang, Sun, Yutong, Hung, Mien-Chie, Ma, Li
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933875/
https://ncbi.nlm.nih.gov/pubmed/29669287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2018.03.078
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!